Venclexta and Vancomycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Venclexta (venetoclax) and Vancomycin (vancomycin). Common drug interactions include leukaemia among females and sepsis among males.

The phase IV clinical study analyzes what interactions people have when they take Venclexta and Vancomycin. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Venclexta?

Venclexta has active ingredients of venetoclax. eHealthMe is studying from 31,425 Venclexta users. Check the latest studies of Venclexta.

What is Vancomycin?

Vancomycin has active ingredients of vancomycin. eHealthMe is studying from 17,165 Vancomycin users. Check the latest studies of Vancomycin.



On Jul, 22, 2026

45 people who take Venclexta and Vancomycin together, and have interactions are studied.

Venclexta and Vancomycin drug interactions.

What are the common drug interactions of Venclexta and Vancomycin, by gender? *:

female:

  1. Leukaemia (blood or bone marrow cancer)
  2. Cough
  3. Fatigue (feeling of tiredness)
  4. Death
  5. Blood calcium decreased
  6. Blood creatinine increased
  7. Blood lactate dehydrogenase increased
  8. Contusion (a type of hematoma of tissue in which capillaries)
  9. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  10. Diarrhoea

male:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Pneumonia
  3. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  4. Haemorrhage (bleeding)
  5. Hypotension (abnormally low blood pressure)
  6. White blood cell count decreased
  7. White blood cell count increased
  8. Haemophilus infection (bacterial infection by haemophilus influenzae)
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Mycobacterial infection

What are the common drug interactions of Venclexta and Vancomycin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Drug hypersensitivity
  2. Erythema (redness of the skin)
  3. Infection
  4. Localised infection (infection at the single location)

10-19:

  1. Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
  2. Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
  3. Bacterial infection
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Pruritus (severe itching of the skin)
  6. Pyrexia (fever)
  7. Rash
  8. White blood cell count increased

20-29:

  1. Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)

30-39:

  1. Bacterial infection
  2. Sepsis (a severe blood infection that can lead to organ failure and death)

40-49:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Haemophilus infection (bacterial infection by haemophilus influenzae)
  3. Cellulitis (infection under the skin)
  4. Pneumonia

50-59:

  1. Death

60+:

  1. Pneumonia
  2. Sepsis (a severe blood infection that can lead to organ failure and death)
  3. Diarrhoea
  4. Ear infection
  5. Fatigue (feeling of tiredness)
  6. Influenza
  7. Leukopenia (less number of white blood cells in blood)
  8. Lymphocytosis (an increase in the number or proportion of lymphocytes in the blood)
  9. Monocytosis (an increase in the number of monocytes circulating in the blood)
  10. Mycobacterial infection

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 20 people, 44.44%
  2. Nausea (feeling of having an urge to vomit): 4 people, 8.89%
  3. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 4 people, 8.89%
  4. Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 4 people, 8.89%
  5. Rashes (redness): 3 people, 6.67%
  6. Febrile Neutropenia (fever with reduced white blood cells): 3 people, 6.67%
  7. Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Venclexta and Vancomycin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Venclexta and Vancomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Venclexta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vancomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Venclexta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vancomycin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on venetoclax and vancomycin (the active ingredients of Venclexta and Vancomycin, respectively), and Venclexta and Vancomycin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: